HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 84.2%

Neg 0% Neu 84.2% Pos 0%

HC Wainwright & Co. analyst Emily Bodnar reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $10 price target.